<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04509011</url>
  </required_header>
  <id_info>
    <org_study_id>2019-05948</org_study_id>
    <nct_id>NCT04509011</nct_id>
  </id_info>
  <brief_title>Autofluorescence vs Clinical Assessment of Parathyroid Glands During Thyroid Surgery</brief_title>
  <official_title>Randomized Controlled Trial of Fluobeam® LX Compared With Clinical Assessment of Parathyroid Glands to Counteract Postoperatively Failing Parathyroid Function With Low Blood Calcium After Thyroid Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the investigation is to study if the use of Fluobeam®-LX to identify&#xD;
      parathyroid glands through autofluorescence during thyroid surgery, may reduce the risk of&#xD;
      postoperative hypoparathyroidism, defined as low PTH in patients undergoing total&#xD;
      thyroidectomy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Temporary and permanent hypoparathyroidism is probably the most important complication of&#xD;
      total thyroidectomy. The rate of permanent hypoparathyroidism in quality registries are in&#xD;
      the range of is 5-7 percent of patients undergoing surgery.&#xD;
&#xD;
      Patients operated on benign disease with total thyroidectomy, and who suffer from permanent&#xD;
      hypoparathyroidism (defined as medication with active Vitamin D analogue therapy for more&#xD;
      than 6 months, are at increased risk of renal insufficiency. They also have, for unclear&#xD;
      reasons, an increased risk of suffering from malignancy, compared to patients without this&#xD;
      complication. Patients with known ischemic heart disease before surgery also have an&#xD;
      increased risk of suffering a new episode of cardiovascular disease. Finally, patients with&#xD;
      permanent hypoparathyroidism have an increased risk of mortality compared to patients without&#xD;
      this complication.&#xD;
&#xD;
      If, by using a technique for autofluorescence (Fluobeam® -LX), one can more accurately&#xD;
      identify and avoid damage to the parathyroid glands during the surgical procedure, this would&#xD;
      be of great importance for patients undergoing total thyroidectomy for thyroid disease.&#xD;
&#xD;
      Patients undergoing total thyroidectomy are randomized to the use of Fluobeam® -LX to detect&#xD;
      the parathyroid glands through autofluorescence during thyroid surgery, or clinical&#xD;
      evaluation only (control). Outcome is evaluated by parathyroid hormon (PTH) levels the first&#xD;
      postoperative day and the need for medication with calcium and Vitamin D up to 6 months&#xD;
      postoperatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention group (intraoperative use of Fluobeam®-LX during thyroid surgery) Control group (clinical assessment and identification of parathyroid glands during thyroid surgery)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The participant is not informed of the assigned group, whereas the the care giver (surgeon) is informed due to the use (or not) of the Fluobeam®-LX.&#xD;
Randomization is performed 1: 1 in blocks of 10 via the Eurocrine quality register platform.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative level of Parathyroid hormone (PTH)</measure>
    <time_frame>First postoperative day</time_frame>
    <description>Low plasma parathyroid hormone (PTH) (below the normal reference range)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative medication with Active vitamin D</measure>
    <time_frame>At discharge (up to 7 days), at 1 month and at 6 months</time_frame>
    <description>Medication with active Vitamin D; dihydrotachysterol (ATC A11CC02), alfacalcidol (ATC A11CC03), or calcitriol (ATC A11CC04) due to postoperative hypocalcaemia. Evaluated by standard questionaire in the database &quot;Eurocrine&quot; (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative medication with oral calcium</measure>
    <time_frame>At discharge (up to 7 days), at 1 month and at 6 months</time_frame>
    <description>Medication with oral calcium; calcium carbonate (A12AA04), and calcium lactate gluconate (A12AA06) Evaluated by standard questionaire in the database &quot;Eurocrine&quot; (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of parathyroid glands</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Number of identified parathyroid glands</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autotransplantation of parathyroid tissue</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Number of autotransplanted parathyroid glands</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excised parathyroid glands</measure>
    <time_frame>One week</time_frame>
    <description>Number of excised parathyroid glands found on the specimen at histopathology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for operation</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Time for surgery (skin to skin) in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>One week</time_frame>
    <description>Hospital stay in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization due to hypocalcaemia</measure>
    <time_frame>One month</time_frame>
    <description>Any subsequent hospitalization within 30 days for hypocalcaemia-related symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hypoparathyroidism Postprocedural</condition>
  <arm_group>
    <arm_group_label>Fluobeam® LX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluobeam® LX is used to detect autofluorescens and identify and evaluate parathyroid glands</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the control group, the parathyroid glands are identified and evaluated by eye (ocular examination).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fluobeam® LX</intervention_name>
    <description>Fluobeam®-LX is used to identify and evaluate parathyroid glands using auto-fluorescence during thyroid surgery.</description>
    <arm_group_label>Fluobeam® LX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with thyroid disease planned for total thyroidectomy regardless of diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous thyroid surgery&#xD;
&#xD;
          -  Previous parathyroid surgery&#xD;
&#xD;
          -  Concurrent parathyroid surgery&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Allergy (contrast agent, iodine)&#xD;
&#xD;
          -  Inability to understand study information&#xD;
&#xD;
          -  Patient unable to participate in planned follow-up program&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders OJ Bergenfelz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders OJ Bergenfelz, PhD</last_name>
    <phone>+46703772086</phone>
    <email>anders.bergenfelz@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erik Nordenström, PhD</last_name>
    <phone>+46734321730</phone>
    <email>erik.nordenstrom@skane.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vienna General Hospital (AKH)</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philipp Riss, PhD</last_name>
      <email>philipp.riss@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette Heie, MD</last_name>
      <phone>+4797647525</phone>
      <email>anette.heie@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University Medical College</name>
      <address>
        <city>Krakow</city>
        <zip>31-008</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Barczyński, PhD</last_name>
      <email>marbar@mp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Muth, MD, PhD</last_name>
      <email>andreas.muth@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital, Department of Surgery, Lund</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anders OJ Bergenfelz, MD, PhD</last_name>
      <phone>+46 46 17 20 86</phone>
      <email>anders.bergenfelz@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Erik Nordenström, MD, PhD</last_name>
      <phone>+46 46 17 23 05</phone>
      <email>erik.nordenstrom@skane.se</email>
    </contact_backup>
    <investigator>
      <last_name>Erik Nordenström, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoparathyroidism</keyword>
  <keyword>PTH</keyword>
  <keyword>Hypocalcemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All individual participant data (IPD) that underlie results in a publication. Individuals are de-identified</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Starting 12 months after publication and for five years</ipd_time_frame>
    <ipd_access_criteria>Researchers within the medical community The principal investigator or the Central Contact Backup will review requests.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

